18F-FAMT in patients with multiple myeloma: Clinical utility compared to 18F-FDG

Annals of Nuclear Medicine

Volumn 26, Issue 10, 2012, Pages 811-816

  Isoda, Atsushi ^a   Higuchi, Tetsuya ^b   Nakano, Sachiko ^b   Arisaka, Yukiko ^b   Kaira, Kyoichi ^c   Kamio, Tadashi ^a   Mawatari, Momoko ^a   Matsumoto, Morio ^a   Sawamura, Morio ^a   Tsushima, Yoshito ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amino acid; Multiple myeloma; PET

Indexed keywords

ALPHA METHYLTYROSINE F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3 FLUORO ALPHA METHYLTYROSINE; 3-FLUORO-ALPHA-METHYLTYROSINE; DIAGNOSTIC AGENT; METIROSINE;

ADULT; AGED; AORTA ARCH; ARTICLE; BONE LESION; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MEDIASTINUM; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIODIAGNOSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT DURATION; TUMOR GROWTH; CLINICAL TRIAL; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METHYLTYROSINES; MIDDLE AGED; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY;

EID: 84874481350     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0645-9     Document Type: Article

References (23)

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
2. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-54.
3. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J ClinOncol. 2007;25:1121-8.
4. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068-76.
5. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989-95.
6. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol. 2005;184:1199-204.
7. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43:1457-63.
8. Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23:7857-63.
9. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50-5.
10. Shortt CP, Gleeson TG, Breen KA, McHugh J, O'Connell MJ, O'Gorman PJ, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. Am J Roentgenol. 2009;192:980-6.
11. Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D, et al. Multiple myeloma: molecular imaging with 11C-methionine PET/CT - initial experience. Radiology. 2007;242:498-508.
12. Tomiyoshi K, Amed K, Muhammad S, Higuchi T, Inoue T, Endo K, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-l-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169-75.
13. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG - preliminary study. Radiology. 2001;220:54-62.
14. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369-78.
15. Miyashita G, Higuchi T, Oriuchi N, Arisaka Y, Hanaoka H, Tominaga H, et al. 18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry. Ann Nucl Med. 2010;24:579-84.
16. Kaira K, Oriuchi N, Otani Y, Yanagitani N, Sunaga N, Hisada T, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019-27.
17. Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, et al. Diagnosis of maxillofacial tumor with l-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med. 2007;21:129-35.
18. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-57.
19. Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiology. 1994;193:441-6.
20. Metser U, Miller E, Lerman H, Even-Sapir E. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. Am J Roentgenol. 2007;189:1203-10.
21. Inoue T, Kim EE, Wong FC, Yang DJ, Bassa P, Wong WH, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med. 1996;37:1472-6.
22. Yamada Y, Uchida Y, Tatsumi K, Yamaguchi T, Kimura H, Kitahara H, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39:1160-6.
23. Hain SF, Beggs AD. C-11 methionine uptake in granulomatous disease. Clin Nucl Med. 2004;29:585-6.